Evidence map›Paper›PMID 35892023›Full record

ArticleClinical kidney journal2022

Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression-real-world clinical practice.

Beatriz Aviles Bueno, Maria Jose Soler, Luis Perez-Belmonte, Anabel Jimenez Millan, Francisco Rivas Ruiz, Maria Dolores Garcia de Lucas

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical kidney journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. The expanding role of semaglutide: beyond glycemic control.Journal of diabetes and metabolic disorders · 2025
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Observational
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Beatriz Aviles BuenoCosta del Sol Hospital, Nephrology Department, Málaga, Spain.ORCID https://orcid.org/0000-0002-0733-8595
Maria Jose SolerVall D´Hebron University Hospital, Nephrology Department, Universitat Autònoma de Barcelona, Barcelona, Spain.ORCID https://orcid.org/0000-0003-3621-0766
Luis Perez-BelmonteRegional University Hospital and Biomedical Research Institute, Internal Medicine Department Málaga, Spain.
Anabel Jimenez MillanPuerto Real University Hospital, Endocrinology Department, Cádiz, Spain.
Francisco Rivas RuizCosta del Sol Hospital, Internal Medicine Department, Málaga, Spain.
Maria Dolores Garcia de LucasResearch Unit, Marbella, Málaga, Spain.
Hospital Costa del Sol · ESHospital Universitario Puerto Real · ESUniversitat Autònoma de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Semaglutide [glucagon-like peptide-1 receptor-agonist (GLP-1RA)] has shown nephroprotective effects in previous cardiovascular studies. However, its efficacy and safety in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) have been rarely studied. Methods: This is a multicenter, retrospective, observational study in patients with T2D and CKD with glycosylated hemoglobin A1c (HbA1c) of 7.5-9.5% treated with subcutaneous semaglutide for 12 months in real-world clinical practice. The main objectives were glycemic control as HbA1c <7% and weight loss >5%. Results: We studied a total of 122 patients, ages 65.50 ± 11 years, 62% men, duration of T2D 12 years, baseline HbA1c 7.57% ± 1.36% and an estimated glomerular filtration rate (eGFR) 50.32 ± 19.21 mL/min/1.73 m Conclusions: In this real-world study, patients with T2D and CKD treated with subcutaneous semaglutide for 12 months significantly improved glycemic control and decreased weight. Albuminuria decreased by >50% in patients with macroalbuminuria. The administration of GLP-1RA in patients with T2D and CKD was safe and well tolerated.

Indexed as

albuminuriadiabetic chronic diseaseGLP-1RAobesitysemaglutide

Identifiers

PMID35892023
PMCPMC9308087
OpenAlexW4223491795

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.